NCT06772753 — drugset

Summary

The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will also complete 2 preparation sessions (4 hours total) before the first experimental session, and follow-up visits after each session to discuss and debrief on the participants subjective experience.

Timeline

Start: 2025-02-05
Primary completion: 2027-06
Completion: 2027-12

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dextromethorphan	Unknown	—	Oral
Subject	Dimethyltryptamine	Unknown	—	Oral
Subject	Dronabinol	Other / unclassified	—	Oral
Subject	Ketamine	Small molecule	—	Oral
Subject	Midomafetamine	Unknown	—	Oral
Comparator	Psilocybin	Other / unclassified	—	Oral

Indications

No indication recorded.

Investigation of Psychedelic Effects in Psychoactive Substances

Summary

Timeline

Publications

Drugs

Indications